Human Metabolome Technologies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Human Metabolome Technologies hat ein Gesamteigenkapital von ¥1.9B und eine Gesamtverschuldung von ¥200.0M, wodurch sich der Verschuldungsgrad auf 10.4% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ¥2.5B bzw. ¥565.0M. Human Metabolome Technologies Das EBIT des Unternehmens beträgt ¥200.0M, so dass der Zinsdeckungsgrad 100 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ¥1.7B.

Wichtige Informationen

10.4%

Verhältnis von Schulden zu Eigenkapital

JP¥200.00m

Verschuldung

Zinsdeckungsgrad	100x
Bargeld	JP¥1.65b
Eigenkapital	JP¥1.93b
Gesamtverbindlichkeiten	JP¥565.00m
Gesamtvermögen	JP¥2.49b

Jüngste Berichte zur Finanzlage

Recent updates

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Jun 07

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

May 22

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Apr 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Mar 23

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Feb 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 6090Die kurzfristigen Aktiva des Unternehmens (¥2.1B) übersteigen seine kurzfristigen Passiva (¥534.0M).

Langfristige Verbindlichkeiten: 6090Die kurzfristigen Vermögenswerte des Unternehmens (¥2.1B) übersteigen seine langfristigen Verbindlichkeiten (¥31.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 6090 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 6090Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 10.4% gestiegen.

Schuldendeckung: 6090Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (128%).

Zinsdeckung: Die Zinszahlungen für die Schulden von 6090 sind durch das EBIT gut gedeckt (100x coverage).

Human Metabolome Technologies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Recent updates

Upcoming dividend of JP¥15.00 per share

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)

Dividend of JP¥15.00 announced

Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024

First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)

Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023

New major risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023

Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)

Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022

Investor sentiment improved over the past week

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022

Insufficient new directors

Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022

First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)

Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)

New 90-day high: JP¥999

Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021

New 90-day low: JP¥741

New 90-day low: JP¥860

Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020

Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen